About DF/HCC
Dana-Farber/Harvard Cancer Center (DF/HCC), an NCI-designated comprehensive cancer center, was founded to integrate and build upon the collective talent and resources of the Harvard cancer research community. Five Boston academic medical institutions—Beth Israel Deaconess Medical Center, Boston Children’s Hospital, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital—and two Harvard Schools—the Harvard Medical School and the Harvard T.H. Chan School of Public Health—combined their scientific strengths to create a rich, collaborative environment that transcends institutional borders. DF/HCC is the powerful successor organization to the Dana-Farber Cancer Institute Comprehensive Cancer Center, one of the original cancer centers designated by the NCI in 1973.
Today, more than 1,100 DF/HCC cancer researchers are working together in innovative clinical-, translational-, basic-, and population-based research programs. Our members receive in excess of $600 million in cancer research funding. Cost-effective shared facilities, or centralized core laboratories, enable access to cutting edge technologies and allow us to build world-class scientific archives. Our members are training and educating the next generation of cancer researchers. Thousands of patients are being enrolled in our clinical trials.
As one of the largest cancer research enterprises in the world, DF/HCC is committed to maximizing the impact of its research for cancer patients and ultimately realizing a world without cancer.
Cancer Center
Administration
Basic Science
Clinical Science
Community Outreach and Engagement
Core Facilities
Initiative to Eliminate Cancer Disparities
Membership
Breast Cancer
Cancer Care Delivery Research
Cancer Cell Biology
Cancer Data Sciences
Cancer Epidemiology
Cancer Genetics and Epigenetics
Cancer Immunology
Cancer Risk, Prevention, and Early Detection
Developmental Therapeutics
Gastrointestinal Malignancies
Gynecologic Cancers
Kidney Cancer
Leukemia
Lung Cancer
Lymphoma and Myeloma
Melanoma
Neuro-Oncology
TRACY T. BATCHELOR Co-Leader
DAPHNE HAAS-KOGAN Co-Leader
SCOTT R. PLOTKIN Co-Leader
MARIO L. SUVA Co-Leader
Prostate Cancer
Bioinformatics Training
SHANNAN HO SUI Co-Director
MEETA MISTRY Co-Director
Biostatistics
Cancer Proteomics
Cell Manipulation
Health Communication
Population Sciences Laboratory Support
Research Pharmacy
Rodent HistoPathology
Single Cell
MANDOVI CHATTERJEE Director
Specialized Histopathology
Survey and Qualitative Methods
Tissue MicroArray And Imaging
Tumor Imaging Metrics
Mouse Engineering
Administration | |||
Deborah Goff, PhD | Vice President, DF/HCC Administration | (617) 632-4044 | |
Amanda Smith | Executive Assistant for Ramesh Shivdasani | (617) 632-3487 | |
Mark Grinstein-Camacho | DF/HCC Administrative Specialist | ||
| |||
Richard Oakley | Communications Director | (617) 632-4276 | |
| |||
Michelle Cox | Senior Director for Core Facilities | (617) 632-3566 | |
Kelly Smith | Program Manager | (617) 632-4104 | |
| |||
Thomas Leonard | Web Systems Architect | (617) 632-3937 | |
| |||
Karen Burns White | Deputy Associate Director | (617) 632-3244 | |
Brittany Michel | Program Manager | ||
Julia Miller | Program Manager | ||
| |||
Jun-Rong Wei, PhD | Director, DFHCC Operations | ||
Jackie Hwang | Program Manager | (617) 632-5685 | |
Erica Fletcher | Grant Administrator | (617) 632-4864 |
For clinical trials administration contact information, visit the Clinical Research section.